

## Treatment-Associated Toxicities Reported by Patients with Early-Stage Invasive Breast Cancer

Running title: Breast Cancer Toxicities

Christopher R. Friese, PhD<sup>1</sup>Jordan M. Harrison, BSN<sup>1</sup>Nancy K. Janz, PhD<sup>2</sup>Reshma Jagsi, MD, DPhil<sup>3</sup>Monica Morrow, MD<sup>4</sup>Yun Li, PhD<sup>5</sup>Ann S. Hamilton, PhD<sup>6</sup>Kevin C. Ward, PhD<sup>7</sup>Allison W. Kurian, MD<sup>8</sup>Steven J. Katz, MD<sup>9\*</sup>Timothy P. Hofer, MD<sup>10\*</sup>

\*Dr. Katz and Dr. Hofer contributed equally to this work

<sup>1</sup>Department of Systems, Populations, and Leadership, School of Nursing, and Institute for Healthcare Policy and Innovation, University of Michigan; <sup>2</sup>Department of Health Behavior and Health Education, School of Public Health, University of Michigan; <sup>3</sup>Department of Radiation Oncology, University of Michigan School of Medicine; <sup>4</sup>Memorial Sloan-Kettering Cancer Center; <sup>5</sup>Department of Biostatistics, University of Michigan School of Public Health; <sup>6</sup>University of Southern California Keck School of Medicine; <sup>7</sup>Rollins School of Public Health, Emory University; <sup>8</sup>Departments of Medicine and Health Research and Policy, Stanford University Medical Center; <sup>9</sup>Departments of Internal Medicine and Health Management and Policy, Schools of Medicine and Public Health, University of Michigan; <sup>10</sup>Veterans Affairs Center for Clinical Management Research, Health Services Research and Development Service Center of Innovation and Department of Internal Medicine, University of Michigan

Correspondence To: Christopher R. Friese, PhD, RN, AOCN®, FAAN, University of Michigan School of Nursing, 400 North Ingalls, #4162, Ann Arbor, MI 48109-5482 (email: [cfriese@umich.edu](mailto:cfriese@umich.edu)) Telephone: 734-647-4308; Fax: 734-647-2416

Text pages: 21

Tables: 1

Figures: 4

Funding: This work was supported by the National Cancer Institute (P01CA163233 to S.J.K.).

Cancer incidence data collection was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; the NCI's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California (USC), and contract HHSN261201000034C awarded to the Public Health Institute.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version record](#). Please cite this article as [doi:10.1002/cncr.30547](https://doi.org/10.1002/cncr.30547).

Cancer incidence data collection in Georgia was supported by contract HHSN261201300015I, Task Order HHSN26100006 from the NCI and cooperative agreement 5NU58DP003875-04-00 from the CDC.

Conflict of interest: none

Author contributions:

Christopher R. Friese: Conceptualization, methodology, investigation, writing-original draft, writing-review and editing, and visualization

Jordan M. Harrison: Investigation, writing-original draft, writing-review and editing

Nancy K. Janz: Conceptualization, methodology, investigation, writing-original draft, and writing-review and editing

Reshma Jagsi: Conceptualization, methodology, investigation, writing-original draft, and writing-review and editing

Monica Morrow: Conceptualization, methodology, investigation, writing-original draft, and writing-review and editing

Yun Li: Methodology, investigation, software, formal analysis, writing-original draft, and writing-review and editing

Ann S. Hamilton: Conceptualization, methodology, investigation, writing-original draft and writing-review and editing

Kevin C. Ward: Conceptualization, methodology, investigation, writing-original draft and writing-review and editing

Allison W. Kurian: Conceptualization, methodology, investigation, writing-original draft, and writing-review and editing

Steven J. Katz: Conceptualization, methodology, investigation, writing-original draft, writing-review and editing, and visualization

Timothy P. Hofer: Methodology, investigation, software, formal analysis, writing-original draft, writing-review and editing

Precis: Our results from a diverse, population-based sample show that nearly half of women treated for early stage breast cancer experienced at least one toxicity they rated as severe/very severe during treatment, with variation observed by treatment modality. Toxicities correlate with physical function and increased healthcare service use.

## ABSTRACT

### *Background*

Patient-reported toxicities help to appraise the breast cancer treatment experience. Yet extant data come from clinical trials and healthcare claims, which may be biased. Using patient surveys, we sought to quantify the frequency, severity, and burden of treatment-associated toxicities.

### *Methods*

Between 2013 and 2014, the iCanCare study surveyed a population-based sample of women residing in Los Angeles County and Georgia with early-stage, invasive breast cancer. We assessed the frequency and severity of toxicities, correlated toxicity severity with unscheduled healthcare use (clinic visits, emergency department visits/hospitalization) and physical health, and examined patient, tumor, and treatment factors associated with reporting increased toxicity severity.

### *Results*

The overall survey response was 71%. From the analyzed cohort of 1,945 women, 866 (45%) reported at least one toxicity that was severe/very severe, 9% reported unscheduled clinic visits for toxicity management, and 5% visited an emergency department or hospital. Factors associated with reporting higher toxicity severity included: chemotherapy receipt (OR 2.2, 95% CI 2.0-2.5), both chemotherapy and radiation therapy receipt (OR 1.3, 95% CI 1.0-1.7), and Latina ethnicity (OR vs whites 1.3, 95% CI 1.1-1.5). A non-significant increase in at least one severe/very severe toxicity report was observed for bilateral mastectomy recipients (OR 1.2, 95% CI 1.0-1.4).

*Conclusions*

Women with early-stage invasive breast cancer report substantial treatment-associated toxicities and related burden. Clinicians should collect toxicity data routinely and offer early intervention.

Toxicity differences by treatment modality may inform decision-making.

Key words: Breast Cancer; treatment experience; treatment-associated toxicities; patient report

Accepted Article

## INTRODUCTION

Cancer treatments have a narrow therapeutic index. Clinicians constantly weigh anticipated benefits of anti-cancer treatments against risks of treatment-associated toxicities. Toxicities may lead to treatment discontinuation,<sup>1,2</sup> costly healthcare service use,<sup>3</sup> and premature death.<sup>4</sup> Toxicities place physical, emotional, and financial burdens on patients and families.<sup>5</sup> Toxicity management also consumes clinician and practice resources.<sup>6</sup>

Despite the burdens placed on patients, families, and healthcare systems, few data sources capture toxicities reliably. Treatment-related toxicity studies generally derive from clinical trials data,<sup>7</sup> health care claims,<sup>8</sup> and single-site patient registries,<sup>9</sup> with notable limitations of generalizability, data quality, and biased reporting. In 2007, a National Cancer Institute-sponsored working group developed a patient-reported version of the Common Terminology Criteria for Adverse Events (CTCAE). The Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE) enables patients to report the frequency, severity, and burden of toxicities and addresses well-documented biases observed with clinician-reported toxicity ratings.<sup>10,11</sup>

Few studies have solicited the toxicity experience directly from diverse, population-based patient samples. Describing the patterns, correlates, and frequency of treatment-associated toxicities from a large population-based sample allows clinicians to understand the actual patient treatment experience outside the narrow confines of rigorously-conducted clinical trials. Such data could inform targeted, proactive efforts to identify patients at risk for burdensome toxicities, enable earlier intervention, and improve quality of life.

In this context, we analyzed data collected from a population-based survey of women diagnosed with early-stage invasive breast cancer. We examined frequency and severity of

toxicities associated with cancer treatment. Next, we explored the correlation between toxicity reports and physical health and healthcare service use. Finally, we examined patient, tumor, and treatment factors associated with toxicities rated as severe or very severe.

## **PATIENTS AND METHODS**

### **SAMPLING AND SURVEY PROCEDURES**

The iCanCare study is a population-based mailed survey of women with early-stage breast cancer. In partnership with the Los Angeles County and Georgia Surveillance Epidemiology and End-Results (SEER) programs, the iCanCare study identified 3,880 women of ages 20 through 79 years who were diagnosed with early-stage breast cancer determined by a definitive breast surgery date between July 1, 2013 and December 31, 2014. Women were sent surveys about 2 months after surgery and completed the survey on average about 7 months after diagnosis. To enable meaningful analyses across racial and ethnic groups, African Americans and Latinas were oversampled in Los Angeles County. The following women were excluded from the iCanCare study sampling protocol: stage III or IV cancer (as the overall project was focused on early-stage patients), Paget's disease, or tumors > 5cm in size. In Los Angeles County, non-Hispanic whites and African Americans aged <50 were excluded due to a competing study in these populations.

The study was approved by the Institutional Review Boards of the University of Michigan and partnering institutions. Informed by Dillman's methods,<sup>12</sup> we solicited participation with a \$20 cash incentive. Study coordinators in respective geographic areas continued to follow up with non-responders, including up to 9 attempted phone calls and 2 repeated mailings. Participants received survey materials to their home address with a statement

that their answers would not be shared individually with their providers. Study materials were printed in English; women with Spanish surnames received Spanish and English materials.<sup>13</sup>

Of 3,880 originally-identified women, 249 were ineligible. From these 3,631 women, 1,053 women were not reached or did not return questionnaires, resulting in an overall response rate of 71% (n=2,578). After excluding 694 women with DCIS or bilateral disease our analytic sample included 1,884 observations in the observed data and 1,945 observations after multiple imputation. SEER registries linked surveys to standardized tumor registry data.

## MEASURES

Except where indicated, measures were collected from patient questionnaires. The primary outcome was treatment-associated toxicities. Informed by the PRO-CTCAE working group<sup>14</sup> and our pilot work,<sup>15</sup> participants rated the severity of seven toxicities – at their worst during cancer treatment – using a 5-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe). The toxicities measured were nausea/vomiting, diarrhea, constipation, pain, arm edema, dyspnea, and breast skin irritation. These toxicities were selected after interviews with survivors and analysis of toxicity reports in pilot work.<sup>15</sup>

As few studies have investigated patient-reported, treatment-associated toxicities, we measured toxicities in three ways. First, we examined the range of severity ratings across toxicities. Next, we constructed a scale by multiplying the number of toxicities reported by severity. For example, a score of 3 might reflect one toxicity rated as severe or three toxicities rated as mild, and a score of 28 would reflect that a patient reported all seven toxicities as very severe.

To examine toxicity burden, we examined physical health and healthcare service use. To measure physical health, we used the 4-item physical function subscale of the Patient Reported

Outcome Measurement Information System (PROMIS) global health measure. The scale is a brief, valid, reliable, precise, and clinically interpretable measure of physical health.<sup>16</sup>

Respondents rated each item on a 5-point ordinal scale. The score was standardized and normalized according to the scoring manual; scores below 40 reflected poor physical health.<sup>17</sup> To measure healthcare service use, we asked patients whether they 1) did not seek help, 2) called/emailed their provider, 3) discussed at a routine visit, 4) discussed at an unscheduled visit, or 5) visited the emergency department/hospital. We classified unscheduled care as either an unscheduled clinic visit, emergency department visit, or inpatient hospitalization for toxicity management.

Patients reported their age, race/ethnicity (white, black, Latina, Asian), education (high school or less, some college, college graduate or more), and prior comorbidity diagnosis—chronic lung disease, heart disease, diabetes, or stroke – (no diagnosis, one condition, two or more conditions). We included four separate variables to capture treatment factors: primary breast surgery (lumpectomy, unilateral mastectomy, bilateral mastectomy), radiation therapy (yes/no), systemic chemotherapy (yes/no), and receipt of both radiation and chemotherapy (yes/no). SEER registries provided tumor information: stage (I or II), grade (1, 2, or 3), and lymph node status (N0 or N1). We calculated the difference between the date of patient survey completion and the cancer diagnosis date.

## ANALYSIS

First, we used descriptive statistics to examine patient, disease, and treatment factors in our analytic sample and then examined these factors in the subset of women who rated at least one toxicity as severe/very severe, as well as in the subset of women who reported unscheduled care for toxicity management. Next, for each of the seven toxicities and corresponding severity



rating, we calculated the proportion of women who also reported healthcare service use (phone call, scheduled visit, unscheduled visit, emergency department visit/hospitalization) for that toxicity. Using the multiplied scale of number of toxicities reported by their severity, we next plotted the corresponding PROMIS physical function scores. Using multivariable regression, we examined two dependent variables – unscheduled care and PROMIS physical function scores – by toxicity score, controlling for patient, tumor, and treatment factors. Finally, we used multivariable ordinal logistic regression with design weights reflecting the probability of selection and non-response to examine the relationship of patient, tumor, and treatment factors to higher levels of toxicity severity.

Unless specified, analyses controlled for geography (Los Angeles County and Georgia) and were weighted to account for differing probabilities of sample selection and non-response.<sup>18</sup> We identified small amounts of missing data (range of 0-3.9% across variables, 93% of observations had complete data). To minimize biased estimates from missing data, we applied a sequential regression multiple imputation framework.<sup>19</sup> We generated five independently-imputed data sets and computed inferential statistics that combined analyses across datasets.<sup>20</sup> Imputation results were indistinguishable from the complete case analysis. Table 1 is based on complete case analysis (N identified in table for each variable) and all subsequent figures and regression results are based on multiply-imputed data (N=1,945).

## RESULTS

Table 1 shows patient characteristics, including women who reported any of the seven measured toxicities as severe/very severe, and those who sought unscheduled care for toxicities via clinic visits, emergency departments, or hospitals.

### **Frequency and Severity of Patient-Reported Toxicities.**

Women with early-stage invasive breast cancer reported a number of toxicities during treatment, many of which were rated as severe or very severe. 132 patients (7%) reported that none of the seven toxicities occurred during treatment. 1,810 women (93%) reported at least one toxicity and 866 of the women in the analytic sample (45%) rated at least one toxicity as severe/very severe. Among the seven toxicities, pain was most frequently reported as severe/very severe (23%), followed by constipation (14%), and breast skin irritation (13%).

#### **Toxicities and Healthcare Service Use.**

Figure 1 shows patient reports of healthcare service use by each toxicity studied and the corresponding severity rating. Across all seven toxicities, 2-4% of patients did not endorse a toxicity rating, but discussed the problem during a routine office visit. Most patients sought help during an office visit (range between 22% and 77% across the seven toxicities); telephone calls/emails and emergency department visits/hospitalizations were less frequently reported. For women who experienced at least one toxicity, 9% sought care through a previously unscheduled clinic visit and 5% visited an emergency department or hospital.

Nausea/vomiting and diarrhea were frequent sources of telephone calls/emails; 29% of patients with very severe nausea/vomiting and 27% of patients with very severe diarrhea called or emailed their provider. Severe arm edema (77%) and very severe skin irritation (71%) were the primary reasons for unscheduled clinic visits. Patients with severe/very severe dyspnea most frequently visited emergency departments or hospitals for toxicity management (28%), followed by patients with severe/very severe arm edema (27%), severe/very severe diarrhea (18%), and severe/very severe pain (18%).

### **Toxicities and Physical Health.**

The mean (SD) physical functioning score on the PROMIS measure was 14.5 (3), reflecting substantial deficits from the optimal score of 50. Figure 2 shows the relationship between the multiplied toxicity rating (number of toxicities and toxicity severity rating) and PROMIS physical scores estimated by a regression model, with corresponding 95% confidence intervals. Higher PROMIS scores reflect better physical functioning and higher toxicity scores reflect more frequent and/or severe toxicity ratings. These scores were averaged across age, comorbid conditions, chemotherapy receipt, employment, marital status, and race/ethnicity. PROMIS-physical functioning scores correlated linearly, negatively, and significantly with toxicity ratings ( $\beta = -0.2$ , 95% CI -0.3 - -0.2). Patients without toxicity had the highest scores, whereas patients who reported all seven toxicities as severe reported scores at the lowest possible score of 10 on the scale.

### **Factors Associated with Reporting at Severe or Very Severe Toxicity.**

Figures 3A-C show the unadjusted differences in toxicity reporting by breast cancer treatment. Toxicity severity varied by chemotherapy receipt (Figure 3A). For example, 29% of chemotherapy recipients reported severe/very severe pain, compared with 19% of women who did not receive chemotherapy. Severe/very severe constipation was reported by 24% of chemotherapy recipients, compared with rates of 9% for women who did not receive chemotherapy. Radiation therapy recipients reported more severe/very severe skin irritation than women who did not receive radiation (22% versus 7%), but did not differ on other toxicities (Figure 3B).

Toxicity severity varied by surgical treatment (Figure 3C). For five of seven toxicities studied, women who received bilateral mastectomy were more likely to report more

severe/severe toxicities (nausea/vomiting, diarrhea, constipation, pain, and shortness of breath). More bilateral mastectomy recipients (37%) reported severe/very severe pain than those receiving unilateral mastectomy (25%) or lumpectomy (18%).

Figure 4 shows the results of a multivariable logistic regression model, which shows significant associations between the category of toxicity, plus patient and treatment factors associated with the severity toxicity. We also included a variable to reflect patient receipt of both chemotherapy and radiation therapy. Three toxicities were more frequently associated with more severe ratings; pain (OR 4.7, 95% CI 4.2-5.3), skin irritation (OR 2.1, 95% CI 1.8-2.5), and constipation (OR 1.5, 95% CI 1.4-1.7). Women who received systemic adjuvant chemotherapy were more likely to report more severe toxicity (OR 2.0, 95% CI 1.7-2.4). Patients who received both chemotherapy and radiation therapy had an additional 30% higher odds of more severe toxicity (OR 1.3, 95% CI 1.0-1.7) over those receiving only chemotherapy. Patients who had bilateral mastectomy were more likely to report higher toxicity (OR 1.2, 95% CI 1.0-1.4) than unilateral mastectomy recipients, but the difference did not reach statistical significance.

Older patients were significantly less likely to report higher toxicity (OR 0.8, 95% CI 0.7-0.8). Patients with more comorbidities were more likely to report higher toxicity (OR 1.4 95% CI 1.3-1.5 for the first comorbidity). Latinas were more likely than white women to report higher toxicity (OR 1.3, 95% CI 1.1-1.5). Compared with college graduates, women with some college education were more likely to report higher toxicity (OR 1.2, 95% CI 1.0-1.3).

## DISCUSSION

In this population-based sample of women with early-stage, invasive breast cancer, a substantial number of patients reported clinically-burdensome toxicities during treatment. A scaled measure that captured the number and severity of toxicities was associated with poorer

physical health and increased healthcare service use, including unscheduled clinic visits, emergency department visits, and inpatient admissions. Compared to those without severe toxicities, women who reported at least one severe toxicity differed in age, comorbidity history, race/ethnicity, and breast cancer treatment. These novel data solicited directly from patients highlight opportunities to improve supportive care through targeted toxicity management and data-informed patient-provider communication.

High rates of burdensome toxicities reported by women with early-stage breast cancer support recent assertions that many women with curable disease suffer “collateral damage” from breast cancer treatment.<sup>21</sup> Nearly one quarter of chemotherapy recipients in our study endorsed severe/very severe nausea/vomiting during their cancer treatment. This finding likely reflects inconsistent adoption of chemotherapy-induced nausea and vomiting guidelines across diverse chemotherapy settings.<sup>22</sup> It is unclear whether patients receive standardized education about toxicities expected during treatment. Targeting toxicities that occur frequently and are reported as severe or very severe is one important clinical intervention to improve outcomes for women with early-stage breast cancer.

Importantly, toxicity severity correlates with clinically significant physical health deficits. Breast cancer survivorship guidelines stress the importance of optimal physical health for breast cancer survivors.<sup>23</sup> Our data suggest burdensome toxicities occur in patients who do not receive chemotherapy and interfere with physical health, which may threaten long-term outcomes. Supportive care programs that extend beyond chemotherapy recipients are needed to reduce toxicity severity, maintain health, and enhance the survivorship period. For example, routine toxicity assessments across chemotherapy, surgery, and radiation therapy clinics would identify high-priority areas for interventions.

Our findings are congruent with a prospective study of Italian women recently diagnosed with breast cancer and treated with adjuvant systemic therapy who completed similar patient-reported toxicity measures.<sup>24</sup> High rates of gastrointestinal symptoms were reported. Compared with the current study, lower rates of pain were reported. In a small, longitudinal study of women receiving doxorubicin-based chemotherapy for early stage breast cancer, the most frequent, severe, and distressing physical symptoms reported included pain.<sup>25</sup> The differences observed may be due to the different survey time points or survey prompts; on average, participants in the iCanCare study completed surveys 7 months after definitive breast surgery. In the survey, women rated the severity of their toxicities at their worst during treatment. While prior work suggests patient recall of toxicities is valid and reliable,<sup>26</sup> we cannot exclude the possibility of recall bias.

Our finding of higher toxicity burdens for non-white patients may explain prior findings of lingering quality of life deficits for Latinas with breast cancer;<sup>27</sup> culturally-sensitive toxicity management interventions may be warranted. Women may perceive that bilateral mastectomy is associated with improved survival and minimal difference in other outcomes.<sup>28</sup> Our data suggest that bilateral mastectomy recipients experience more toxicity severity relative to other surgical options; pain reports are nearly double those compared with women who receive lumpectomy. Decision aids for women that present patient-reported outcome rates across surgical modalities may bridge knowledge gaps. If women were aware of the pain differences reported by procedure, their treatment preferences may differ. Given the differential effects of chemotherapy and radiation therapy, it is not surprising that women who received both of these treatments reported higher toxicity severity than uni-modal treatment; targeted interventions may be warranted in women who receive multi-modal treatment.

Patients and providers seek to boost the value of cancer care services. Despite excellent survival rates, cancer treatment often leads to costly toxicity management, including emergency department visits and hospitalizations,<sup>29</sup> and unscheduled clinic visits that strain busy clinicians. Cancer care value may improve if toxicities can be managed proactively, before they worsen. Researchers have examined the efficacy of routine toxicity assessments coupled with notification of aberrant results to providers, with mixed results.<sup>29,30</sup> Our results underscore the need for further research that examine novel strategies to reduce preventable treatment toxicities.

Strengths of our study include an excellent response rate, a diverse patient sample, and patient-centered measures of toxicity and healthcare service use. Unlike chart review and claims-based approaches, our use of patient-reported measures may overcome documented concerns for clinician reporting of toxicities<sup>31</sup> and measurement challenges in healthcare claims.<sup>8</sup> However, several aspects of our study merit comment. First, our data are cross sectional and causal relationships cannot be assumed. We did not have access to medical records to ascertain regimens, dosages, and timing of chemotherapy and radiation, nor do we have clinician reports of toxicities and health care service use, which could address concerns for patient recall. The survey timing should be considered when interpreting toxicity reports and healthcare service use. While our work was informed by the NCI's PRO-CTCAE working group,<sup>14</sup> the study measures are not identical in terms of timing of administration and rating categories. While the regions studied are diverse, results may not be generalizable to other settings. Given the overall project goal of understanding treatment patterns in early-stage breast cancer, our results are germane to patients with early-stage disease; similar investigations in patients with advanced disease, would identify toxicity frequency and intensity in the setting of more frequent multi-modal treatments.

Nearly half of women with early-stage, invasive breast cancer experience toxicities they perceive as severe or very severe, including women who do not receive adjuvant systemic chemotherapy. These findings have important clinical implications. The toxicity burden faced by patients may be greater than acknowledged by clinicians, and warrants routine assessment during and between clinic visits. Differential toxicity patterns identified in this diverse, population-based sample of women may help clinicians when they review risks and benefits of breast cancer treatment options. Data-driven patient education and communication tools that compare patient-reported outcomes from breast cancer treatments could inform decision making and prepare women for the treatment experience. Pain control is challenging for many women across diverse treatment plans. Gastrointestinal toxicities plague chemotherapy recipients despite available practice guidelines. Additional studies must help clinicians distinguish the duration of treatment-associated toxicities and their impact on therapy completion. Finally, our data speak to the need for culturally-tailored interventions coupled with management protocols to improve quality of life for patients at risk for burdensome toxicities.

## **ACKNOWLEDGEMENTS**

This work was supported by the National Cancer Institute (P01CA163233 to S.J.K.).

Cancer incidence data collection was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention's (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; the NCI's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California (USC), and contract HHSN261201000034C awarded to the Public Health Institute.



Cancer incidence data collection in Georgia was supported by contract HHSN261201300015I, Task Order HHSN26100006 from the NCI and cooperative agreement 5NU58DP003875-04-00 from the CDC. The ideas and opinions expressed herein are those of the authors. The State of California, Department of Public Health, the NCI, and the CDC and their Contractors and Subcontractors had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

We acknowledge our project staff (Mackenzie Crawford and Kiyana Perrino from the Georgia Cancer Registry; Jennifer Zelaya, Pamela Lee, Maria Gaeta, Virginia Parker, and Renee Bickerstaff-Magee from USC; Rebecca Morrison, Rachel Tocco, Alexandra Jeanpierre, Stefanie Goodell, Rose Juhasz, Paul Abrahamse, Kent Griffith, and Irina Bondarenko from the University of Michigan). We acknowledge with gratitude our survey respondents.

Accepted Article

**REFERENCES**

1. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. *J Clin Oncol*. 2004;22(21):4302-4311.
2. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. *J Clin Oncol*. 2003;21(24):4524-31.
3. Vandyk AD, Harrison MB, Macartney G, Ross-White A, Stacey D. Emergency department visits for symptoms experienced by oncology patients: a systematic review. *Support Care Cancer*. 2012;20(8):1589-1599.
4. Klepin BHD, Pitcher BN, Ballman K V, et al. Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance). *J Oncol Pract*. 2014;10(5):e285-92.
5. Martinez KA, Friese CR, Kershaw T, Given CW, Fendrick M, Northouse L. Effect of a Nurse-Led Psychoeducational Intervention on Healthcare Service Utilization Among Adults With Advanced Cancer. *Oncol Nurs Forum*. 2015;42(4):E310-E318.
6. Paessens BJ, von Schilling C, Berger K, et al. Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. *Ann Oncol*. 2011;22(10):2310-9.
7. Lamont EB, Herndon James E 2nd, Weeks JC, et al. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. *Med Care*. 2008;46(3):303.

8. Barcenas CH, Niu J, Zhang N, et al. Risk of Hospitalization According to Chemotherapy Regimen in Early-Stage Breast Cancer. *J Clin Oncol*. 2014;32(19):2010-2017.
9. Hassett MJ, Rao SR, Brozovic S, et al. Chemotherapy-related hospitalization among community cancer center patients. *Oncologist*. 2011;16(3):378-87.
10. Dueck AC, Mendoza TR, Mitchell S a., et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *JAMA Oncol*. 2015;85259.
11. Atkinson TM, Li Y, Coffey CW, et al. Reliability of adverse symptom event reporting by clinicians. *Qual Life Res*. 2012;21(7):1159-64.
12. Dillman DA, Smyth JD, Christian LM. *Internet, Mail, and Mixed-Mode Surveys: The Tailored Design Method*. 2014.
13. Hamilton AS, Hofer TP, Hawley ST, et al. Latinas and breast cancer outcomes: Population-based sampling, ethnic identity, and acculturation assessment. *Cancer Epidemiol Biomarkers Prev*. 2009;18(7):2022-2029.
14. Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Natl Cancer Inst*. 2014;106(9).
15. Harrison JM, Stella PJ, LaVasseur B, et al. Toxicity-Related Factors Associated With Use of Services Among Community Oncology Patients. *J Oncol Pract*. 2016;In press. doi:10.1200/JOP.2016.010959.
16. Schalet BD, Hays RD, Jensen SE, Beaumont JL, Fries JF, Cella D. Validity of PROMIS physical function measures in diverse clinical samples. *J Clin Epidemiol*. 2016. doi:10.1016/j.jclinepi.2015.08.039.

7. Patient-Reported Outcomes Measurement Information System. PROMIS Physical Function Scoring Manual. 2013:1-14. Available at: [https://www.assessmentcenter.net/documents/PROMIS Physical Function Scoring Manual.pdf](https://www.assessmentcenter.net/documents/PROMIS%20Physical%20Function%20Scoring%20Manual.pdf). Accessed May 31, 2016.
8. Groves RM, Fowler Jr FJ, Couper MP, Lepkowski JM, Singer E, Tourangeau R. Survey Methodol. John Wiley & Sons; 2011.
9. Raghunathan TE, Lepkowski JM, Van Hoewyk J, Solenberger P. A multivariate technique for multiply imputing missing values using a sequence of regression models. *Surv Methodol*. 2001;27(1):85-96.
0. Rubin DB, ed. *Multiple Imputation for Nonresponse in Surveys*. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 1987.
1. Helwick C. Dr. Susan Love: Time to Address “Collateral Damage” of Breast Cancer Treatment. *ASCO Post*. 2016. Available at: <http://www.ascopost.com/issues/may-25-2016/dr-susan-love-time-to-address-collateral-damage-of-breast-cancer-treatment/>.
2. Gilmore JW, Peacock NW, Gu A, et al. Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. *J Oncol Pract*. 2014;10(1):68-74.
3. Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. *CA Cancer J Clin*. 2015;66(1):43-73.
4. Montemurro F, Mittica G, Cagnazzo C, et al. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer. *JAMA Oncol*. 2016;2(4):445-52.
5. Byar KL, Berger AM, Bakken SL, Cetak MA. Impact of Adjuvant Breast Cancer

- Chemotherapy on Fatigue, Other Symptoms, and Quality of Life. *Oncol Nurs Forum*. 2006;33(1):E18-E26.
6. Harrison JM, Stella PJ, LaVasseur B, et al. Toxicity-Related Factors Associated With Use of Services Among Community Oncology Patients. *J Clin Oncol*. 2016;12(8):e818-e827.
  7. Janz NK, Friese CR, Li Y, Graff JJ, Hamilton AS, Hawley ST. Emotional well-being years post-treatment for breast cancer: prospective, multi-ethnic, and population-based analysis. *J Cancer Surviv*. 2014;8(1):131-42.
  8. Hamelinck VC, Bastiaannet E, Pieterse AH, et al. Patients' preferences for surgical and adjuvant systemic treatment in early breast cancer: A systematic review. *Cancer Treat Rev*. 2014;40(8):1005-1018.
  9. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. *J Clin Oncol*. 2016;34(6):557-65.
  0. Mooney KH, Beck SL, Friedman RH, Farzanfar R, Wong B. Automated monitoring of symptoms during ambulatory chemotherapy and oncology providers' use of the information: a randomized controlled clinical trial. *Support Care Cancer*. 2014.
  1. Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. *Nat Rev Clin Oncol*. 2016;13(5):319-25.

## Figure Legends

### **Figure 1: Distribution of Patient-Reported Healthcare Service use by Each Toxicity and Rated Severity**

ER=Emergency Room. Results reported are based on weighted, imputed data.

### **Figure 2: Physical Health Scores by Toxicity Severity**

PROMIS=Patient-Reported Outcomes Measurement Information System. Higher physical health scores reflect better physical functioning. Higher toxicity severity scores reflect increased toxicity frequency and/or worse severity. Toxicity scores were inversely proportional to physical health ( $\beta = -0.2$ , 95% CI -0.3 - -0.2). Results reported are based on weighted, imputed data.

### **Figures 3A-C: Toxicity Severity by Breast Cancer Treatment.**

3A: Differences in toxicity severity by chemotherapy receipt. N=1,945

3B: Differences in toxicity severity by radiation therapy receipt. N=1,945

3C: Differences in toxicity severity by breast cancer surgery. N=1,945

Results reported are based on weighted, imputed data.

### **Figure 4: Factors Associated with Reporting More Severe Toxicities**

GED=Graduate equivalent diploma. Dbl. mast=Bilateral mastectomy. Results reported are based on weighted, imputed data. Note: the odds ratio represents the odds of being in a higher vs. a lower level of toxicity severity.

**Table 1: Patient Sample Characteristics by Toxicity Report and Report of Healthcare Service Use**

	N	Reported one or more toxicities as severe or very severe	Sought unscheduled care (clinic visit, Emergency Department, or Hospital)
<b>Age (years), Mean</b>	1,884	60	59
<b>Diagnosis to survey (days), Mean</b>	1,878	207	218
			<b>Percent</b>
<b>PATIENT FACTORS</b>			
<b>Race/Ethnicity</b>			
White	1,057	40	11
Black	321	52	16
Latina	315	53	17
Asian	141	48	6
Other/unknown/missing	50	52	17
<b>Education</b>			
Less than high school	211	57	16
High school graduate	331	37	9
Some college	623	48	12
College graduate or more	698	42	13
<b>Comorbidities</b>			
0	1,101	41	12
1	527	49	13
2 or more	247	52	15
<b>TUMOR FACTORS</b>			
<b>Stage</b>			
1	1,264	41	11
2	620	52	16
<b>Lymph nodes positive</b>			
No	1,502	42	11
Yes	382	53	18
<b>TREATMENT FACTORS</b>			
<b>Surgical treatment</b>			
Lumpectomy	1,138	39	12
Unilateral Mastectomy	393	48	12
Bilateral Mastectomy	338	58	16
<b>Radiation treatment</b>			
No/future radiation	975	51	14
Current/past radiation	890	37	11
<b>Adjuvant chemotherapy</b>			

No chemotherapy	1,134	35	8
Chemotherapy	736	60	19
<b>Received both chemotherapy and radiation therapy</b>			
No	1,667	43	12
Yes	217	59	19
<b>Site</b>			
Georgia	1,049	42	12
Los Angeles County	835	47	13

---

Data are n (%), mean (SD), unless otherwise stated. Percentages are based on unweighted data.

Accepted Article






Figure 1: Distribution of Patient-Reported Healthcare Service use by Each Toxicity and Rated Severity  
ER=Emergency Room. Results reported are based on weighted, imputed data.

Figure 1 shows patient reports  
66x48mm (300 x 300 DPI)

Accep





Figure 2: Physical Health Scores by Toxicity Severity

PROMIS=Patient-Reported Outcomes Measurement Information System. Higher physical health scores reflect better physical functioning. Higher toxicity severity scores reflect increased toxicity frequency and/or worse severity. Toxicity scores were inversely proportional to physical health ( $\beta = -0.2$ , 95% CI  $-0.3 - -0.2$ ). Results reported are based on weighted, imputed data.

Figure 2 shows the relationshi  
66x48mm (300 x 300 DPI)

ACCE


Distribution of symptom severity by treatment status



Figures 3A-C: Toxicity Severity by Breast Cancer Treatment.  
 3A: Differences in toxicity severity by chemotherapy receipt. N=1,945  
 Toxicity severity varied by ch  
 66x48mm (300 x 300 DPI)

Accep

Distribution of symptom severity by treatment status




Figures 3A-C: Toxicity Severity by Breast Cancer Treatment.  
 3B: Differences in toxicity severity by radiation therapy receipt. N=1,945

adiation therapy recipients re  
 66x48mm (300 x 300 DPI)

Accepted

### Distribution of symptom severity by treatment status



Figures 3A-C: Toxicity Severity by Breast Cancer Treatment.  
3C: Differences in toxicity severity by breast cancer surgery. N=1,945  
Results reported are based on weighted, imputed data.  
Toxicity severity varied by su  
66x48mm (300 x 300 DPI)

Accept




Figure 4: Factors Associated with Reporting More Severe Toxicities  
 GED=Graduate equivalent diploma. Dbl. mast=Bilateral mastectomy. Results reported are based on weighted, imputed data. Note: the odds ratio represents the odds of being in a higher vs. a lower level of toxicity severity.

Figure 4 shows the results of  
 66x48mm (300 x 300 DPI)

AcceJ